If you find this podcast useful please give it a rating and review on iTunes by clicking here
Jeremy Skillington CEO of Poolbeg Pharma discusses how 'EncOVac', a consortium led by Poolbeg, has been awarded €2.3m in non-dilutive grant funding to progress its Oral Vaccine Platform under the Irish Government's Disruptive Technologies Innovation Fund.
Highlights
Taking place over three years, the collaboration between Poolbeg Pharma, University College Dublin, Trinity College Dublin and AnaBio Technologies will result in the development of an oral vaccine candidate to a Phase I ready state. The resulting technology will serve as a platform for additional oral vaccine candidates for a wide range of pathogens, initially targeting bacterial infections. Poolbeg is proud to play a role in the development of the next generation of vaccine technologies that can protect the world from infectious diseases.
To read the full RNS click here